Obstructive renal injury: From fluid mechanics to molecular cell biology

Open Access Journal of Urology

Volumn 2, Issue 1, 2010, Pages 41-55

  Ucero, Alvaro C ^a   Gonçalves, Sara ^b   Benito Martin, Alberto ^a   Santamaría, Beatriz ^a   Ramos, Adrian M ^a   Berzal, Sergio ^a   Ruiz Ortega, Marta ^a   Egido, Jesus ^a   Ortiz, Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Fluid mechanics; Molecular cell biology; Renal injury; Urinary tract obstruction

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; BIOLOGICAL MARKER; BOSENTAN; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR7; COLONY STIMULATING FACTOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

APOPTOSIS; CELL DAMAGE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CYTOLOGY; DRUG TARGETING; FIBROSIS; GLOMERULOSCLEROSIS; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TRANSGENIC ANIMAL; URETER OBSTRUCTION; URINARY TRACT OBSTRUCTION;

EID: 77953368752     PISSN: None     EISSN: 11791551     Source Type: Book Series    
DOI: None     Document Type: Review

References (188)

1. Thomas D. Fetal uropathy. Br J Urol. 1990;66(3):225-231.
2. NAPRTCS. North American Pediatric Renal Trials and Collaborative Studies, 2008 Annual Report. Rockville, MD, EMMES2008.
3. Lewis M, Shaw J, Reid C, Evans J, Webb N, Verrier-Jones K. Demography and management of childhood established renal failure in the UK (chapter 13). Nephrol Dial Transplant. 2007;22 Suppl 7:vii165-vii175.
4. Kaufman J, Dhakal M, Patel B, Hamburger R. Community-acquired acute renal failure. Am J Kidney Dis. 1991:17(2):191-198.
5. Sacks S, Aparicio S, Bevan A, Oliver D, Will E, Davison A. Late renal failure due to prostatic outflow obstruction: a preventable disease. BMJ. 1989;298(6667):156-159.
6. USRDS. United States Renal Data System, 2005 Annual Data report: Atlas of end stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2005
7. Woodward M, Frank D. Postnatal management of antenatal hydronephrosis. BJU Int. 2002;89(2):149-156.
8. Chevalier R. Perinatal obstructive nephropathy. Semin Perinatol. 2004;28(2):124-131.
9. Ravanan R, Tomson C. Natural history of postobstructive nephropathy: a single-center retrospective study. Nephron Clin Pract. 2007;105(4): c165-c170.
10. Abou El-Ghar M, Shokeir A, Refaie H, El-Diasty T. MRI in patients with chronic obstructive uropathy and compromised renal function: a sole method for morphological and functional assessment. Br J Radiol. 2008;81(968):624-629.
11. Better O, Arieff A, Massry S, Kleeman C, Maxwell M. Studies on renal function after relief of complete unilateral ureteral obstruction of three months' duration in man. Am J Med. 1973;54(2):234-240.
12. Chevalier R. Obstructive nephropathy and the developing kidney: too little or too much angiotensin? Kidney Int. 2004;65(4):1517-1518.
13. Vanderheyden T, Kumar S, Fisk N. Fetal renal impairment. Semin Neonatol. 2003;8(4):279-289.
14. Yohannes P, Hanna M. Current trends in the management of posterior urethral valves in the pediatric population. Urology. 2002;60(6):947-953.
15. Chevalier R. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol. 2006;2(3):157-168.
16. Klahr S. Obstructive nephropathy. Intern Med. 2000;39(5):355-361.
17. Selkurt E, Deetjen P, Brechtelsbauer H. Tubular pressure gradients and filtration dynamics during urinary stop flow in the rat. Pflugers Arch Gesamte Physiol Menschen Tiere. 1965;286(1):19-35.
18. Klahr S. Pathophysiology of obstructive nephropathy: a 1991 update. Semin Nephrol. 1991;11(2):156-168.
19. Jaenike J. The renal response to ureteral obstruction: a model for the study of factors which influence glomerular filtration pressure. J Lab Clin Med. 1970;76(3):373-382.
20. Tanner G, Knopp L. Glomerular blood flow after single nephron obstruction in the rat kidney. Am J Physiol. 1986;250(1 Pt 2):F77-F85.
21. Idbohrn H, Muren A. Renal blood flow in experimental hydronephrosis. Acta Physiol Scand. 1956;38(2):200-206.
22. Vaughan EJ, Shenasky JN, Gillenwater J. Mechanism of acute hemodynamic response to ureteral occlusion. Invest Urol. 1971;9(2): 109-118.
23. Gaudio K, Siegel N, Hayslett J, Kashgarian M. Renal perfusion and intratubular pressure during ureteral occlusion in the rat. Am J Physiol. 1980;238(3):F205-F209.
24. Harris K, Klahr S, Schreiner G. Obstructive nephropathy: from mechanical disturbance to immune activation? Exp Nephrol. 1993;1(3): 198-204.
25. Wen J, Frøkiaer J, Jørgensen T, Djurhuus J. Obstructive nephropathy: an update of the experimental research. Urol Res. 1999;27(1):29-39.
26. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int. 1995;47(5):1285-1294.
27. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int. 1996;49(4):1110-1119.
28. Klahr S, Ishidoya S, Morrissey J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis. 1995;26(1):141-146.
29. Moridaira K, Morrissey J, Fitzgerald M, et al. ACE inhibition increases expression of the ETB receptor in kidneys of mice with unilateral obstruction. Am J Physiol Renal Physiol. 2003;284(1):F209-F217.
30. Esteban V, Lorenzo O, Rupérez M, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15(6):1514-1529.
31. Hegarty N, Young L, O'Neill A, Watson R, Fitzpatrick J. Endothelin in unilateral ureteral obstruction: vascular and cellular effects. J Urol. 2003;169(2):740-744.
32. Miyajima A, Chen J, Kirman I, Poppas D, Darracott Vaughan EJ, Felsen D. Interaction of nitric oxide and transforming growth factor-beta1 induced by angiotensin II and mechanical stretch in rat renal tubular epithelial cells. J Urol. 2000;164(5):1729-1734.
33. Ricardo S, Ding G, Eufemio M, Diamond J. Antioxidant expression in experimental hydronephrosis: role of mechanical stretch and growth factors. Am J Physiol. 1997;272(6 Pt 2):F789-F798.
34. Chevalier R, Thornhill B, Gomez R. EDRF modulates renal hemodynamics during unilateral ureteral obstruction in the rat. Kidney Int. 1992;42(2):400-406.
35. Eddy A. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(4):353-365.
36. Lan H, Nikolic-Paterson D, Mu W, Atkins R. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int. 1995;48(3):753-760.
37. Diamond J, Kees-Folts D, Ricardo S, Pruznak A, Eufemio M. Early and persistent up-regulated expression of renal cortical osteopontin in experimental hydronephrosis. Am J Pathol. 1995;146(6):1455-1466.
38. Yoo K, Thornhill B, Forbes M, et al. Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int. 2006;70(10):1735-1741.
39. Chevalier R, Cachat F. Role of angiotensin II in chronic ureteral obstruction. Contrib Nephrol. 2001;(135):250-260.
40. Misseri R, Meldrum D, Dagher P, Hile K, Rink R, Meldrum K. Unilateral ureteral obstruction induces renal tubular cell production of tumor necrosis factor-alpha independent of inflammatory cell infiltration. J Urol. 2004;172(4 Pt 2):1595-1599.
41. Misseri R, Meldrum D, Dinarello C, et al. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol. 2005;288(2):F406-F411.
42. Morrissey J, Klahr S. Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int. 1997;52(4):926-933.
43. Morrissey J, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol. 1999;276(1 Pt 2):F39-F45.
44. Li J, Brasier A. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol. 1996;10(3):252-264.
45. Morrissey J, Klahr S. Transcription factor NF-kappaB regulation of renal fibrosis during ureteral obstruction. Semin Nephrol. 1998;18(6): 603-611.
46. Donnahoo K, Meldrum D, Shenkar R, Chung C, Abraham E, Harken A. Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J Urol. 2000;163(4):1328-1332.
47. Ricardo S, Levinson M, DeJoseph M, Diamond J. Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. Kidney Int. 1996;50(6):2002-2010.
48. Morrissey J, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol. 1998;274(3 Pt 2):F580-F586.
49. Vielhauer V, Anders H, Mack M, et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol. 2001;12(6):1173-1187.
50. Weber G, Ashkar S, Glimcher M, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271(5248):509-512.
51. Le Meur Y, Tesch G, Hill P, et al. Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. J Leukoc Biol. 2002;72(3):530-537.
52. Gaboury J, Woodman R, Granger D, Reinhardt P, Kubes P. Nitric oxide prevents leukocyte adherence: role of superoxide. Am J Physiol. 1993;265(3 Pt 2):H862-H867.
53. Vodovotz Y. Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease. Nitric Oxide. 1997;1(1):3-17.
54. Kaneto H, Ohtani H, Fukuzaki A, et al. Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. Kidney Int. 1999;56(6):2137-2146.
55. Sanz A, Santamaría B, Ruiz-Ortega M, Egido J, Ortiz A. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol. 2008;19(9):1634-1642.
56. Ortiz A, Justo P, Sanz A, Lorz C, Egido J. Targeting apoptosis in acute tubular injury. Biochem Pharmacol. 2003;66(8):1589-1594.
57. Gobe G, Axelsen R. Genesis of renal tubular atrophy in experimental hydronephrosis in the rat. Role of apoptosis. Lab Invest. 1987;56(3):273-281.
58. Misaki T, Yamamoto T, Suzuki S, et al. Decrease in tumor necrosis factor-alpha receptor-associated death domain results from ubiquitin-dependent degradation in obstructive renal injury in rats. Am J Pathol. 2009;175(1):74-83.
59. Cachat F, Lange-Sperandio B, Chang A, et al. Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. Kidney Int. 2003;63(2):564-575.
60. Jones E, Shahed A, Shoskes D. Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin II inhibition in ureteral obstruction. Urology. 2000;56(2):346-351.
61. Dai C, Yang J, Liu Y. Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem. 2003;278(14):12537-12545.
62. Tsutsui H, Nakanishi K, Matsui K, et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol. 1996;157(9):3967-3973.
63. Lorz C, Ortiz A, Justo P, et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol. 2000;11(7):1266-1277.
64. Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renal injury. Nephrol Dial Transplant. 1999;14(8):1831-1834.
65. Lange-Sperandio B, Fulda S, Vandewalle A, Chevalier R. Macro-phages induce apoptosis in proximal tubule cells. Pediatr Nephrol. 2003;18(4):335-341.
66. Power R, Doyle B, Higgins D, Brady H, Fitzpatrick J, Watson R. Mechanical deformation induced apoptosis in human proximal renal tubular epithelial cells is caspase dependent. J Urol. 2004;171(1):457-461.
67. Lieberthal W, Menza S, Levine J. Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol. 1998;274(2 Pt 2):F315-F327.
68. Lieberthal W, Levine J. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol. 1996;271(3 Pt 2): F477-F488.
69. Miyajima A, Chen J, Poppas D, Vaughan EJ, Felsen D. Role of nitric oxide in renal tubular apoptosis of unilateral ureteral obstruction. Kidney Int. 2001;59(4):1290-1303.
70. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol. 2006;17(11):2992-2998.
71. Qi W, Chen X, Poronnik P, Pollock C. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol. 2006;38(1):1-5.
72. Strutz F. How many different roads may a cell walk down in order to become a fibroblast? J Am Soc Nephrol. 2008;19(12):2246-2248.
73. Lin S, Kisseleva T, Brenner D, Duffield J. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol. 2008;173(6):1617-1627.
74. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci U S A. 2006;103(38):14098-14103.
75. Epstein J, McCarthy G. Progress in HIV and AIDS care. J Can Dent Assoc. 1996;62(11):866-867.
76. Iwano M, Plieth D, Danoff T, Xue C, Okada H, Neilson E. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110(3):341-350.
77. Lee D, Huang E, Ward H. Tight junction biology and kidney dysfunction. Am J Physiol Renal Physiol. 2006;290(1):F20-F34.
78. Lange-Sperandio B, Trautmann A, Eickelberg O, et al. Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. Am J Pathol. 2007;171(3):861-871.
79. Wolf G, Mueller E, Stahl R, Ziyadeh F. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is medi-ated by endogenous transforming growth factor-beta. J Clin Invest. 1993;92(3):1366-1372.
80. Shin G, Kim W, Yim H, Kim M, Kim H. Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor-beta1 expression in acute ureteral obstruction. Kidney Int. 2005;67(3):897-908.
81. Fern R, Yesko C, Thornhill B, Kim H, Smithies O, Chevalier R. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest. 1999;103(1):39-46.
82. Verrecchia F, Chu M, Mauviel A. Identification of novel TGF-beta/ Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001;276(20):17058-17062.
83. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int. 1993;44(2):313-321.
84. Fukuda K, Yoshitomi K, Yanagida T, Tokumoto M, Hirakata H. Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy. Am J Physiol Renal Physiol. 2001;281(3):F513-F521.
85. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: patho-logic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15(1):1-12.
86. Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A. 2004;101(23):8687-8692.
87. Taneda S, Hudkins K, Topouzis S, et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol. 2003;14(10):2544-2555.
88. Yokoi H, Sugawara A, Mukoyama M, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis. Am J Kidney Dis. 2001;38(4 Suppl 1):S134-S138.
89. Mazzieri R, Masiero L, Zanetta L, et al. Control of type IV collagenase activity by components of the urokinaseplasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 1997;16(9): 2319-2332.
90. Ishidoya S, Ogata Y, Fukuzaki A, Kaneto H, Takeda A, Orikasa S. Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats. J Urol. 2002;167(3):1503-1507.
91. Hruska K, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol. 2000;279(1):F130-F143.
92. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF- beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9(7):964-968.
93. Itoh S, Thorikay M, Kowanetz M, et al. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem. 2003;278(6):3751-3761.
94. Trachtman H, Futterweit S, Singhal P. Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun. 1995;207(1):120-125.
95. Shihab F, Yi H, Bennett W, Andoh T. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int. 2000;58(3):1174-1185.
96. Hochberg D, Johnson C, Chen J, et al. Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase. Lab Invest. 2000;80(11):1721-1728.
97. Manucha W, Oliveros L, Carrizo L, Seltzer A, Vallés P. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney Int. 2004;65(6):2091-2107.
98. Bascands J, Schanstra J. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int. 2005;68(3):925-937.
99. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803.
100. Mezzano S, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38(3 Pt 2):635-638.
101. Touyz R, Schiffrin E. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52(4):639-672.
102. Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7(11):936-953.
103. Brenner B, Cooper M, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
104. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857-1863.
105. Mathiesen E, Hommel E, Hansen H, Smidt U, Parving H. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ. 1999;319(7201):24-25.
106. Jafar T, Schmid C, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta- analysis of patient-level data. Ann Intern Med. 2001;135(2):73-87.
107. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43 (5 Suppl 1):S1-S290.
108. Strippoli G, Bonifati C, Craig M, Navaneethan S, Craig J. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;(4):CD006257.
109. Beharrie A, Franc-Guimond J, Rodriguez M, Au J, Zilleruelo G, Abitbol C. A functional immature model of chronic partial ureteral obstruction. Kidney Int. 2004;65(4):1155-1161.
110. Topcu S, Pedersen M, Nørregaard R, et al. Candesartan prevents long- term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. Am J Physiol Renal Physiol. 2007;292(2): F736-F748.
111. Fujinaka H, Miyazaki Y, Matsusaka T, et al. Salutary role for angiotensin in partial urinary tract obstruction. Kidney Int. 2000;58(5):2018-2027.
112. Chen C, Park M, Forbes M, et al. Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat. Am J Physiol Renal Physiol. 2007;292(3):F946-F955.
113. Coleman C, Minor J, Burt L, Thornhill B, Forbes M, Chevalier R. Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. Am J Physiol Renal Physiol. 2007:293(1):F262-F268.
114. Zucchetta P, Carasi C, Marzola M, et al. Angiotensin converting enzyme inhibition worsens the excretory phase of diuretic renography for obstructive hydronephrosis. J Urol. 2001;165(6 Pt 2): 2296-2299.
115. Hanssens M, Keirse M, Vankelecom F, Van Assche F. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991;78(1):128-135.
116. Tabacova S, Little R, Tsong Y, Vega A, Kimmel C. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2003;12(8):633-646.
117. Pryde P, Sedman A, Nugent C, Barr MJ. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993:3(9):1575-1582.
118. Cooper W, Hernandez-Diaz S, Arbogast P, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-2451.
119. Briggs G, Nageotte M. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother. 35(7-8):859-861.
120. Klahr S, Morrissey J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7-S14.
121. Satoh M, Kashihara N, Yamasaki Y, et al. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2001;12(2):317-325.
122. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int. 1998;53(4):937-944.
123. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int. 1994;45(6):1637-1647.
124. Ferrario C. Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens. 2002;20(5):805-807.
125. Esteban V, Ruperez M, Sánchez-López E, et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res. 2005;96(9):965-973.
126. Esteban V, Heringer-Walther S, Sterner-Kock A, et al. Angiotensin- (1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One. 2009;4(4):e5406.
127. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol. 1999;277(5 Pt 2):F766-F772.
128. Kent D, Jafar T, Hayward R, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18(6):1959-1965.
129. Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 2000;58(6):2301-2313.
130. Baricos W, Cortez S, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999;10(4): 790-795.
131. Waiser J, Dell K, Böhler T, et al. Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. Nephrol Dial Transplant. 2002;17(9): 1568-1577.
132. Sato M, Muragaki Y, Saika S, Roberts A, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest. 2003;112(10):1486-1494.
133. Inazaki K, Kanamaru Y, Kojima Y, et al. Smad3 deficiency attenuates renal fibrosis, inflammation,and apoptosis after unilateral ureteral obstruction. Kidney Int. 2004;66(2):597-604.
134. Lan H, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003;14(6):1535-1548.
135. Schaefer L, Macakova K, Raslik I, et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol. 2002;160(3):1181-1191.
136. Dudas P, Argentieri R, Farrell F. BMP-7 fails to attenuate TGF- beta1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells. Nephrol Dial Transplant. 2009;24(5): 1406-1416.
137. Park S, Choi M, Song I, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta- induced epithelial-to-mesenchymal transition. J Am Soc Nephrol. 2007;18(5):1497-1507.
138. Vallés P, Pascual L, Manucha W, Carrizo L, Rüttler M. Role of endogenous nitric oxide in unilateral ureteropelvic junction obstruction in children. Kidney Int. 2003;63(3):1104-1115.
139. Morrissey J, Ishidoya S, McCracken R, Klahr S. Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol. 1996;7(10):2202-2212.
140. Valles P, Manucha W. H+-ATPase activity on unilateral ureteral obstruction: interaction of endogenous nitric oxide and angiotensin II. Kidney Int. 2000;58(4):1641-1651.
141. Huang A, Palmer L, Hom D, Valderrama E, Trachtman H. The role of nitric oxide in obstructive nephropathy. J Urol. 2000;163(4):1276-1281.
142. Yang J, Shultz R, Mars W, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest. 2002;110(10):1525-1538.
143. Matsuo S, López-Guisa J, Cai X, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-over- expressing mice. Kidney Int. 2005;67(6):2221-2238.
144. Oda T, Jung Y, Kim H, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001;60(2):587-596.
145. Ingelfinger J. Forestalling fibrosis. N Engl J Med. 2003;349(23): 2265-2266.
146. Fogo A. The potential for regression of renal scarring. Curr Opin Nephrol Hypertens. 2003;12(3):223-225.
147. Miyajima A, Kosaka T, Seta K, Asano T, Umezawa K, Hayakawa M. Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J Urol. 2003;169(4): 1559-1563.
148. Kim K, Lee E, Cha S, et al. Transcriptional regulation of NF-kappaB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy. Exp Mol Pathol. 2009;86(2):114-120.
149. Meldrum K, Metcalfe P, Leslie J, Misseri R, Hile K, Meldrum D. TNF-alpha neutralization decreases nuclear factor-kappaB activation and apoptosis during renal obstruction. J Surg Res. 2006;131(2): 182-188.
150. Rámila D, Ardura J, Esteban V, et al. Parathyroid hormone-related protein promotes inflammation in the kidney with an obstructed ureter. Kidney Int. 2008;73(7):835-847.
151. Klein J, Gonzalez J, Duchene J, et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J. 2009;23(1):134-142.
152. Kitagawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol. 2004;165(1):237-246.
153. Tsou C, Peters W, Si Y, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest. 2007;117(4):902-909.
154. Eis V, Luckow B, Vielhauer V, et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15(2):337-347.
155. Anders H, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest. 2002;109(2):251-259.
156. Ophascharoensuk V, Giachelli C, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999;56(2):571-580.
157. Inguaggiato P, Gonzalez-Michaca L, Croatt A, Haggard J, Alam J, Nath K. Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. Kidney Int. 2001;60(6):2181-2191.
158. Ophascharoensuk V, Fero M, Hughes J, Roberts J, Shankland S. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med. 1998;4(5):575-580.
159. Chevalier R, Peters C. Congenital urinary tract obstruction: Proceedings of the State-Of-The-Art Strategic Planning Workshop-National Institutes of Health, Bethesda, Maryland, USA, 11-12 2002. Pediatr Nephrol. 2003;18(6):576-606.
160. Huang W, Peters C, Zurakowski D, et al. Renal biopsy in congenital ureteropelvic junction obstruction: evidence for parenchymal maldevelopment. Kidney Int. 2006;69(1):137-143.
161. Chevalier R. Biomarkers of congenital obstructive nephropathy: past, present and future. J Urol. 2004;172(3):852-857.
162. Yang Y, Hou Y, Wang C, Ji S. Renal expression of epidermal growth factor and transforming growth factor-beta1 in children with congenital hydronephrosis. Urology. 2006;67(4):817-821.
163. Yang Y, Zhou X, Gao H, Ji S, Wang C. The expression of epidermal growth factor and transforming growth factor-beta1 in the stenotic tissue of congenital pelvi-ureteric junction obstruction in children. J Pediatr Surg. 2003;38(11):1656-1660.
164. Palmer L, Maizels M, Kaplan W, Firlit C, Cheng E. Urine levels of transforming growth factor-beta 1 in children with ureteropelvic junction obstruction. Urology. 1997;50(5):769-773.
165. El-Sherbiny M, Mousa O, Shokeir A, Ghoneim M. Role of urinary transforming growth factor-beta1 concentration in the diagnosis of upper urinary tract obstruction in children. J Urol. 2002; 168(4 Pt 2):1798-1800.
166. Furness Pr, Maizels M, Han S, Cohn R, Cheng E. Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. J Urol. 1999; 162(3 Pt 2):1033-1036.
167. Taha M, Shokeir A, Osman H, Abd El-Aziz AA, Farahat S. Pelviureteric junction obstruction in children: the role of urinary transforming growth factor-beta and epidermal growth factor. BJU Int. 2007;99(4):899-903.
168. Haramaki R, Tamaki K, Fujisawa M, Ikedo H, Haramaki N, Okuda S. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis. 2001;38(6):1191-1198.
169. De Muro P, Faedda R, Fresu P, et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res. 2004;49(3):293-298.
170. Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation. 2007;83(4):448-457.
171. Honkanen E, Teppo A, Törnroth T, Groop P, Grönhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant. 1997;12(12):2562-2568.
172. Knerr I, Nyul Z, Miller J, et al. Increased endothelin-1 and decreased adrenomedullin gene expression in the stenotic tissue of congenital pelvi-ureteric junction obstruction in children. BJU Int. 2001;87(7):667-671.
173. Grandaliano G, Gesualdo L, Bartoli F, et al. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int. 2000;58(1):182-192.
174. Bartoli F, Gesualdo L, Paradies G, et al. Renal expression of monocyte chemotactic protein-1 and epidermal growth factor in children with obstructive hydronephrosis. J Pediatr Surg. 2000;35(4): 569-572.
175. Taha M, Shokeir A, Osman H, Abd el-Aziz AA, Farahat S. Diagnosis of ureteropelvic junction obstruction in children: role of endothelin-1 in voided urine. Urology. 2007;69(3):560-564.
176. Chiou Y, Chiu N, Wang S, Cheng H, Tang M. Factors associated with the outcomes of children with unilateral ureteropelvic junction obstruction. J Urol. 2004;171(1):397-402.
177. Shokeir A, Taha M. Role of urinary tubular enzymes in evaluation of children with ureteropelvic junction narrowing under conservative management. Urology. 2009;73(5):1016-1020.
178. Carr M, Peters C, Retik A, Mandell J. Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy. J Urol. 1994;151(2):442-445.
179. Taha M, Shokeir A, Osman H, Abd El-Aziz AA, Farahat S. Obstructed versus dilated nonobstructed kidneys in children with congenital ureteropelvic junction narrowing: role of urinary tubular enzymes. J Urol. 2007;178(2):640-646.
180. Shokeir A. Role of urinary biomarkers in the diagnosis of congenital upper urinary tract obstruction. Indian J Urol. 2008;24(3): 313-319.
181. Benito-Martín A, Ucero A, Santamaría B, et al. Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy. Nefrologia. 2009;29(1):13-19.
182. Seseke F, Thelen P, Ringert R. Characterization of an animal model of spontaneous congenital unilateral obstructive uropathy by cDNA microarray analysis. Eur Urol. 2004;45(3):374-381.
183. Higgins D, Lappin D, Kieran N, et al. DNA oligonucleotide microarray technology identifies fisp-12 among other potential fibrogenic genes following murine unilateral ureteral obstruction (UUO): modulation during epithelial-mesenchymal transition. Kidney Int. 2003;64(6):2079-2091.
184. Hauser P, Kainz A, Perco P, et al. Transcriptional response in the unaffected kidney after contralateral hydronephrosis or nephrectomy. Kidney Int. 2005;68(6):2497-2507.
185. Silverstein D, Travis B, Thornhill B, et al. Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. Kidney Int. 2003;64(1):25-35.
186. Kypreou K, Kavvadas P, Karamessinis P, et al. Altered expression of calreticulin during the development of fibrosis. Proteomics. 2008;8(12):2407-2419.
187. Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med. 2006;12(4):398-400.
188. Vlahou A, Schanstra J, Frokiaer J, et al. Establishment of a European Network for Urine and Kidney Proteomics. J Proteomics. 2008;71(4):490-492.